DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $33 | -93.6% | 1,500 | -94.0% | 0.00% | -88.9% |
| Q3 2023 | $512 | -19.5% | 24,800 | +15.1% | 0.01% | -18.2% |
| Q2 2023 | $636 | +28.2% | 21,540 | 0.0% | 0.01% | +10.0% |
| Q1 2023 | $496 | -14.2% | 21,540 | +3.7% | 0.01% | -16.7% |
| Q4 2022 | $578 | -99.9% | 20,780 | 0.0% | 0.01% | -14.3% |
| Q3 2022 | $638,000 | +17.1% | 20,780 | +12.3% | 0.01% | +27.3% |
| Q2 2022 | $545,000 | -8.4% | 18,511 | +0.0% | 0.01% | +10.0% |
| Q1 2022 | $595,000 | -21.3% | 18,510 | +9.2% | 0.01% | -23.1% |
| Q4 2021 | $756,000 | +894.7% | 16,943 | +1029.5% | 0.01% | +1200.0% |
| Q3 2021 | $76,000 | -35.6% | 1,500 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $118,000 | +37.2% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $86,000 | -48.8% | 1,500 | -25.0% | 0.00% | -50.0% |
| Q4 2020 | $168,000 | – | 2,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |